Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kazuya Ohama has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Hirokazu Kimura

    Department of Clinical Engineering, Faculty of Medical Science and Technology, Gunma Paz University, Takasaki 370-0006, Japan

    1 shared publication
  • Hiroyuki Miyakawa

    Graduate School of Health Science, Gunma Paz University, Takasaki 370-0006, Japan

    1 shared publication
  • Masaaki Nakayama

    Division of Research Control,St Luke’s International University,Tokyo,Japan; Division of Research Management,St. Luke's International University,Tokyo,Japan; Advanced Medical Science Research Center,Gumma Paz College,Takasaki,Japan, Japan

    1 shared publication

Latest Publications

  • Open Access

    A Critical Role of Neutrophil-Driven Amplification of Chronic Microinflammation in the Biocompatibility of Hemodialysis

    by Masaaki Nakayama, Hiroyuki Miyakawa, Kazuya Ohama, Hirokazu Kimura

    This review highlights recent insights into the pathophysiology and therapeutic strategies for improving biocompatibility in hemodialysis. Hemodialysis activates the innate immune system, particularly the complement cascade and neutrophils, leading to acute microinflammation. Interleukin-8 (IL-8), which increases during dialysis, promotes neutrophil chemotaxis and neutrophil extracellular trap (NET) formation, triggering myeloperoxidase (MPO) release and oxidative stress. Neutrophil accumulation in atherosclerotic plaques exacerbates vascular inflammation through IL-6 upregulation. Elevated levels of IL-8, MPO, and NET-related biomarkers are associated with increased all-cause and cardiovascular mortality in dialysis patients. Strategies to mitigate these effects include the use of advanced membrane materials (e.g., AN69, vitamin E-coated, polymethyl methacrylate), novel dialysis modalities (e.g., high-volume online hemodiafiltration, cool dialysate, hydrogen-enriched dialysate), and citrate-based anticoagulation. These approaches aim to suppress complement activation, reduce oxidative stress, and limit neutrophil-induced damage. Enhancing biocompatibility is crucial for reducing cardiovascular complications and improving outcomes in dialysis patients. Suppressing the innate immune response during dialysis may become a future cornerstone in extracorporeal blood purification therapy.